palmitic acid o-toluidide | 54662-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: palmitic acid o-toluidide
• 英文别名: Palmitinsaeure-o-toluidid；Hexadecanoic acid o-tolylamide；N-(2-methylphenyl)hexadecanamide
• CAS: 54662-37-2
• 化学式: C₂₃H₃₉NO
• 分子量: 345.569
• InChiKey: ZSMXQQRQXNUYSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  25
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  邻甲苯胺 、 棕榈酰氯 生成 palmitic acid o-toluidide
  参考文献：
  名称：

  New Compounds - Substituted Amides

  摘要：

  DOI：

  10.1021/ja01869a601

文献信息

• MEANS OF STABILIZING THROMBIN AND COMPOSITIONS
  申请人：INTERNATIONAL REAGENTS CORPORATION

  公开号：EP1221479A1

  公开（公告）日：2002-07-10

  The present invention is to provide a means for the stabilization of thrombin and a stabilized thrombin-containing composition having a good reproducibility of the measurement. There are provided a means for the stabilization of thrombin, characterized in that, effective amount (s) of one or more which is/are selected from calcium ion, surfactant and protein is/are contained and a stabilized thrombin-containing composition as well. There are also provided a means for the stabilization of thrombin where an effective amount of a water-soluble organic acid is jointly used in addition to the above and a stabilized thrombin-containing composition as well. There is further provided a thrombin-containing composition having an extremely high measurement reproducibility using thrombin and stabilizer for thrombin where one or more high-molecular polysaccharides or synthetic polymers is/are contained in the above-mentioned stabilized thrombin-containing composition.

  本发明旨在提供一种稳定凝血酶的方法和一种测量重现性良好的含稳定凝血酶组合物。 本发明提供了一种稳定凝血酶的方法，其特征在于含有有效量的一种或多种选自钙离子、表面活性剂和蛋白质的物质，以及一种稳定的含凝血酶组合物。此外，还提供了一种稳定凝血酶的方法，其中除上述物质外，还联合使用了有效量的水溶性有机酸，并提供了一种含稳定凝血酶的组合物。还提供了一种使用凝血酶和凝血酶稳定剂具有极高测量重现性的含凝血酶组合物，在上述稳定化的含凝血酶组合物中含有一种或多种高分子多糖或合成聚合物。
• New Compounds - Substituted Amides
  作者：C Bowen、L Smith

  DOI：10.1021/ja01869a601

  日期：1940.12
• METHOD FOR STABILIZING THROMBIN
  申请人：SYSMEX CORPORATION

  公开号：EP1221479B1

  公开（公告）日：2006-11-22
• Means for stabilization of thrombin and compositions
  申请人：Okuda Masahiro

  公开号：US20060246052A1

  公开（公告）日：2006-11-02

  The present invention is to provide a means for the stabilization of thrombin and a stabilized thrombin-containing composition having a good reproducibility of the measurement. There are provided a means for the stabilization of thrombin, characterized in that, effective amount(s) of one or more which is/are selected from calcium ion, surfactant and protein is/are contained and a stabilized thrombin-containing composition as well. There are also provided a means for the stabilization of thrombin where an effective amount of a water-soluble organic acid is jointly used in addition to the above and a stabilized thrombin-containing composition as well. There is further provided a thrombin-containing composition having an extremely high measurement reproducibility using thrombin and stabilizer for thrombin where one or more high-molecular polysaccharides or synthetic polymers is/are contained in the above-mentioned stabilized thrombin-containing composition.
• Modifications of the Ethanolamine Head in <i>N</i>-Palmitoylethanolamine:  Synthesis and Evaluation of New Agents Interfering with the Metabolism of Anandamide
  作者：Séverine Vandevoorde、Kent-Olov Jonsson、Christopher J. Fowler、Didier M. Lambert

  DOI：10.1021/jm0209679

  日期：2003.4.1

  The endogenous fatty acid amide anandamide (AEA) has, as a result of its actions on cannabinoid and vanilloid receptors, a number of important pharmacological properties including effects on nociception, memory processes, spasticity, and cell proliferation. Inhibition of the metabolism of AEA, catalyzed by fatty acid amide hydrolase (FAAH), potentiates the actions of AEA in vivo and therefore may be a useful target for drug development. In the present study, we have investigated whether substitution of the headgroup of the endogenous alternative FAAH substrate palmitoylethanolamide (PEA) can result in the identification of novel compounds preventing AEA metabolism. Thirty-seven derivatives of PEA were synthesized, with the C16 long chain of palmitic acid kept intact, and comprising 20 alkylated, 12 aromatic, and 4 halogenated amides. The ability of the PEA derivatives to inhibit FAAH-catalyzed hydrolysis of [H-3]AEA was investigated using rat brain homogenates as a source of FAAH. Inhibition curves were analyzed to determine the potency of the inhibitable fraction (pI(50) values) and the maximal attained inhibition for the compound, given that solubility in an aqueous environment is a major issue for these compounds. In the alkylamide family, palmitoylethyl-amide and palmitoylallylamide were inhibitors of AEA metabolism with PI50 values of 5.45 and 5.47, respectively. Halogenated derivatives (Cl and Br) exhibit PI50 values of similar to5.5 but rather low percentages of maximal inhibition. The -OH group of the ethyl head chain of N-palmitoylethanolamine was not necessary for interaction with FAAH. Amides containing aromatic moieties were less potent inhibitors of AEA metabolism. Compounds containing amide and ester bonds, 13 and 37, showed PI50 values of 4.99 and 5.08, respectively. None of the compounds showed obvious affinity for CB1 or CB2 receptors expressed on Chinese hamster ovary (CHO) cells. It is concluded that although none of the compounds were dramatically more potent than PEA itself at reducing the metabolism of AEA, the lack of effect of the compounds at CB1 and CB2 receptors makes them useful templates for development of possible therapeutic FAAH inhibitors.